WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Efficacy Framework_v2, Study treatments include Zortress, Clinically suspected Acute Rejection can be defined by fever, Treated BPAR episode assessed with Graded Biopsy, Clinically suspected Acute Rejection can be defined by graft tenderness, 12 months has a detrimental effect on Graft survival, Biopsy is assessed by Biopsy grade, Serum Creatinine (SCr) can be thresholded at 25%, Acute Rejection Events consist of BPAR (Biopsy Proven Acute Rejection), Study treatments include Astagraf XL, BPAR (Biopsy Proven Acute Rejection) can be assessed in Laboratory, Acute Rejection Events assessed at 12 months, Serum Creatinine (SCr) is measured post-transplant, What are the efficacy points for prophylaxis of acute rejection in kidney transplant subject? are evaluated for Study treatments, Biopsy grade can be IB, Biopsy grade can be III, Laboratory can be Local, BPAR (Biopsy Proven Acute Rejection) can be assessed 24 months, Acute Rejection Events consist of Graft Loss, Clinically suspected Acute Rejection can be defined by Serum Creatinine (SCr), Graded Biopsy is analogous to Biopsy grade